Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 4)
|
Atea Pharmaceuticals, Inc. (Name of Issuer) |
Common Stock, par value $0.001 (Title of Class of Securities) |
04683R106 (CUSIP Number) |
03/31/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 04683R106 |
| 1 | Names of Reporting Persons
JPM Partners LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
5,866,025.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
6.9 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13G
|
| CUSIP No. | 04683R106 |
| 1 | Names of Reporting Persons
Jean-Pierre Sommadossi | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
8,876,453.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
10.1 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
| Item 1. | |
| (a) | Name of issuer:
Atea Pharmaceuticals, Inc. |
| (b) | Address of issuer's principal executive offices:
225 Franklin Street, Suite 2100, Boston, MA 02110. |
| Item 2. | |
| (a) | Name of person filing:
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:
JPM Partners LLC; and
Jean-Pierre Sommadossi |
| (b) | Address or principal business office or, if none, residence:
The business address of JPM Partners LLC is 2 Avery Street #21E, Boston, MA 02111. The business address of Dr. Sommadossi is c/o Atea Pharmaceuticals, Inc., 225 Franklin Street, Suite 2100, Boston, MA 02110. |
| (c) | Citizenship:
JPM Partners LLC is a Delaware limited liability company. Dr. Sommadossi is a citizen of the United States. |
| (d) | Title of class of securities:
Common Stock, par value $0.001 |
| (e) | CUSIP No.:
04683R106 |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
The information contained on the cover pages to this Schedule 13G is incorporated by reference to this Item 4.
The ownership information below represents beneficial ownership of shares of Common Stock as of March 31, 2025, based upon 85,579,475 shares of Common Stock outstanding as of May 9, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2025.
JPM Partners LLC is the record holder of 5,866,025 shares of Common Stock. Dr. Sommadossi is the manager of JPM Partners LLC and may be deemed to share beneficial ownership of the securities held by JPM Partner LLC. Dr. Sommadossi beneficially owns an additional 3,010,428 shares of Common Stock, which includes 2,709,488 shares of Common Stock subject to stock options that are currently exercisable or will become exercisable within 60 days of March 31, 2025. |
| (b) | Percent of class:
See Item 11 of each of the cover pages hereto. |
| (c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
Sole power to vote or to direct the vote: See Item 5 of each of the cover pages hereto. | |
| (ii) Shared power to vote or to direct the vote:
Shared power to vote or direct the vote: See Item 6 of each of the cover pages hereto. | |
| (iii) Sole power to dispose or to direct the disposition of:
Sole power to dispose or to direct the disposition of: See Item 7 of each of the cover pages hereto. | |
| (iv) Shared power to dispose or to direct the disposition of:
Shared power to dispose or to direct the disposition of: See Item 8 of each of the cover pages hereto. | |
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable
| |
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
| Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
Comments accompanying signature:
99: Joint Filing Agreement (previously filed).